GIOSTAR Chairman and Co-Founder Dr. Anand Srivastava recently spoke with Healthcare Weekly about stem cells, COVID-19, and numerous other topics.
Tag: stem cell research
GIOSTAR continues exploring new strategies for managing the world’s most debilitating diseases. Most recently, Dr. Anand Srivastava conducted research on the use of an Ayurvedic medicinal product to address diabetes.
Under the direction of GIOSTAR Co-Founder Dr. Anand Srivastava, a patient was treated with a topical application of mesenchymal stem cells. Remarkably, the patient saw their psoriasis regress completely after only one month.
For more than two decades, Dr. Anand Srivastava and GIOSTAR have been at the forefront of stem cell therapy and research. The company is currently in process of FDA approval for groundbreaking clinical trials regarding Type 2 Diabetes, which impacts roughly 1 in 10 Americans.
Under the direction of Dr. Srivastava, the patient was treated with Mesenchymal Stem Cell Conditioned Media (MSC-CM), which was applied topically to affected areas daily. Remarkably, after only one month, the patient saw their psoriasis regress completely.
Dr. Gellis continues his insightful discussion with Dr. Anand Srivastava about the ever-evolving landscape of regenerative medicine.
This installment of GIOTalk features a helpful overview of Dr. Anand Srivastava’s ground-breaking discoveries in the field of stem cell research, along with his views on the future of regenerative medicine.
GIOSTAR Co-Founder Dr. Anand Srivastava speaks with a budding young journalist about stem cell therapy and research.